Flavivirus group antigen Antibody (D1-4G2-4-15 (4G2)) - Azide and BSA Free

Human C3/36 cell line. Flow cytometry image submitted by a verified customer review.

Flow Cytometry: Flavivirus group antigen Antibody (D1-4G2-4-15 (4G2)) [PE] [NBP2-52709PE] - Mk2 cell line was infected with ZIKA virus at 72 p.o.i and the sample was stained and analyzed by flow cytometry. Image from verified customer review. Image using the PE form of this antibody.

ELISA on Dengue Virus-Like Particles using NBP2-52709. Dengue Virus Serotype 2 VLPs were coated onto a plate at 5ug/ml. Anti-flavivirus antibody added to plate in a 3-fold serial dilution starting at 1000 ng/ml. Detection performed using HRP labelled goat anti-mouse IgG.

• Reactivity: V-Vi
• Applications: WB, ELISA, Flow, ICC/IF, IHC, B/N, CyTOF-ready, ICC/IF
• Clone: D1-4G2-4-15 (4G2)
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: 1 mg/ml

Flavivirus group antigen Antibody (D1-4G2-4-15 (4G2)) - Azide and BSA Free Summary

• Description: Novus Biologicals Mouse Flavivirus group antigen Antibody (D1-4G2-4-15 (4G2)) - Azide and BSA Free (NBP2-52709) is a recombinant monoclonal antibody validated for use in IHC, WB, ELISA, Flow and ICC/IF. Anti-Flavivirus group antigen Antibody: Cited in 22 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: This recombinant Flavivirus group antigen Antibody (D1-4G2-4-15 (4G2)) was prepared from Dengue Virus type 2 antigens.
• Specificity: This Flavivirus group antigen Antibody (D1-4G2-4-15 (4G2)) recognises flavivirus group specific antigens (Dengue virus, West Nile Virus, Japanese Encephalitis, Yellow Fever Virus, Zika virus etc). It binds to the fusion loop at the extremity of domain II of protein E.
• Isotype: IgG2a Kappa
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA 1:100 - 1:2000
  • Flow Cytometry 1:10 - 1:1000
  • Immunocytochemistry/ Immunofluorescence
  • Immunofluorescence 1:10 - 1:500
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin
  • Neutralization
  • Western Blot 1:100 - 1:2000

Reactivity Notes

Dengue Virus, Zika Virus, West Nile Virus, Yellow Fever Virus, Flaviviridae.

Packaging, Storage & Formulations

• Storage: Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
• Buffer: PBS
• Preservative: 0.02% Proclin 300
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for Flavivirus group antigen Antibody (D1-4G2-4-15 (4G2)) - Azide and BSA Free

• Envelope Protein
• Protein E

Background

Flaviviruses are a group of seventy enveloped, positive-sense single stranded RNA viruses belonging to the Flaviviridae family (1-5). Flaviviruses are typically transmitted through arthropods, like mosquitoes and ticks, and can infect humans causing outbreaks and serious illness or death worldwide (1-5). These well-known viral pathogens include dengue virus (DENV), West Nile virus (WNV), Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), Yellow Fever virus (YFV), and Zika virus (ZIKV) (1-5). Flaviviruses consist of ~10.7 kb RNA genome with one open reading frame (ORF) that is flanked by 5' and 3' untranslated regions (UTRs) (1, 2, 6). The ORF encodes for a polyprotein that is made up of three structural proteins, the capsid (C), premembrane (prM), and envelope (E) proteins, and seven non-structural (NS) proteins (NS1, NS2A/B, NS3, NS4A, 2K, NS4B, and NS5) (1, 2, 5, 6).

The Flavivirus group antigen antibody binds to the fusion loop at the distal end of domain II (EDII) of protein E. Flavivirus E is a glycoprotein that is the main antigen for membrane fusion between virus and host and entry into the cell, as well as inducing protective immunity by stimulating neutralizing antibodies (2, 4, 6). The E protein is 495 amino acids (aa) in length and has a theoretical molecular weight between 55 - 72 kDa, which varies based on glycosylation sites (2). Flavivirus E protein contains three domains (EDI, EDII, and EDIII) followed by a stem that contents to the helix-transmembrane domains (TMDs, TM1 and TM2) (2, 4, 6). The EDII contains an S-S bridge at its distal end and functions as a fusion loop (FL) for virus-mediated membrane fusion and antibody binding (2). Given the important role of Flavivirus protein E in host cell infection and membrane fusion, it has become a target for flavivirus disease prevention and treatment (2, 5).

Alternative names for Flavivirus group antigen include Envelope Protein and Protein E.

References

1. Ngono, A. E., & Shresta, S. (2018). Immune Response to Dengue and Zika. Annual review of immunology. https://doi.org/10.1146/annurev-immunol-042617-053142

2. Rey, F. A., Stiasny, K., Vaney, M. C., Dellarole, M., & Heinz, F. X. (2018). The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO reports. https://doi.org/10.15252/embr.201745302

3. Zhang, X., Jia, R., Shen, H., Wang, M., Yin, Z., & Cheng, A. (2017). Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections. Viruses. https://doi.org/10.3390/v9110338

4. Laureti, M., Narayanan, D., Rodriguez-Andres, J., Fazakerley, J. K., & Kedzierski, L. (2018). Flavivirus Receptors: Diversity, Identity, and Cell Entry. Frontiers in immunology. https://doi.org/10.3389/fimmu.2018.02180

5. Boldescu, V., Behnam, M., Vasilakis, N., & Klein, C. D. (2017). Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Nature reviews. Drug discovery. https://doi.org/10.1038/nrd.2017.33

6. Crill, W. D., & Chang, G. J. (2004). Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. Journal of virology, 78(24), 13975-13986. https://doi.org/10.1128/JVI.78.24.13975-13986.2004

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Flavivirus group antigen Antibody (NBP2-52709)(25)

Publications using NBP2-52709

• Carla Bianca Luena Victorio, Wisna Novera, Arun Ganasarajah, Joanne Ong, Melisyaa Thomas, Jonas Wu, Hilary Si Yin Toh, Alfred Xuyang Sun, Eng Eong Ooi, Ann-Marie Chacko Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells Journal of Translational Medicine 2024-02-02 [PMID: 38308299]
• Liu M, Chen Y, Twu N et al. A novel goose-origin Tembusu virus exhibits pathogenicity in day-old chicks with evidence of direct contact transmission Poultry Science 2023-11-01 [PMID: 38128459] (ICC/IF)
• Grunwald V, Ngo H, Formanski J et al. Development of Zika Virus E Variants for Pseudotyping Retroviral Vectors Targeting Glioblastoma Cells International Journal of Molecular Sciences 2023-09-23 [PMID: 37833934]
• Johnson RM, Stopard IJ, Byrne HM et al. Investigating the dose-dependency of the midgut escape barrier using a mechanistic model of within-mosquito dengue virus population dynamics bioRxiv : the preprint server for biology 2023-09-29 [PMID: 37808804] (Virus)
• Fang E, Li M, Liu X et al. NS1 Protein N-Linked Glycosylation Site Affects the Virulence and Pathogenesis of Dengue Virus Vaccines 2023-05-08 [PMID: 37243063] (WB)
• Wollner C, Richner M, Hassert M, et al. A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity bioRxiv 2021-01-07 (WB, Human)
• Carla Bianca Luena Victorio, Arun Ganasarajah, Wisna Novera, Joanne Ong, Rasha Msallam, Ann-Marie Chacko Translocator protein (TSPO) is a biomarker of Zika virus (ZIKV) infection-associated neuroinflammation Emerging Microbes & Infections 2024-04-25 [PMID: 38662785]
• Jeong GU, Lee S, Kim DY et al. Zika Virus Infection Induces Interleukin-1beta-Mediated Inflammatory Responses by Macrophages in the Brain of an Adult Mouse Model Journal of virology 2023-05-16 [PMID: 37191498] (FLOW)
• Kedarinath K, Fox CR, Crowgey E et al. CD24 Expression Dampens the Basal Antiviral State in Human Neuroblastoma Cells and Enhances Permissivity to Zika Virus Infection Viruses 2022-08-06 [PMID: 36016357] (FLOW, Human)
• Martinez-Liu C, Machain-Williams C, Martinez-Acuna N et al. Development of a Rapid Gold Nanoparticle-Based Lateral Flow Immunoassay for the Detection of Dengue Virus Biosensors 2022-07-07 [PMID: 35884298]
• Fonseka CL, Hardman CS, Woo J et al. Dengue virus co-opts innate type 2 pathways to escape early control of viral replication Communications biology 2022-07-22 [PMID: 35869167] (ICC, B/N, Virus - HPV)
• Gallichotte EN, Henein S, Nivarthi U et al. Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity Cell reports 2022-06-07 [PMID: 35675766]
• Lim ZQ, Ng QY, Oo Y et al. Enterovirus-A71 exploits peripherin and Rac1 to invade the central nervous system EMBO reports 2021-04-19 [PMID: 33871166]
• Francese R, Civra A, Donalisio M et al. Anti-Zika virus and anti-Usutu virus activity of human milk and its components PLoS Negl Trop Dis Oct 1 2020 [PMID: 33027261] (IHC, Monkey)
• Riva V, Garbelli A, Brai A et al. Unique Domain for a Unique Target: Selective Inhibitors of Host Cell DDX3X to Fight Emerging Viruses J. Med. Chem. 2020-08-18 [PMID: 32787106]
  
  Details:
  Citation using the HRP format of this antibody.
• Hans C. Leier, Jules B. Weinstein, Jennifer E. Kyle, Joon-Yong Lee, Lisa M. Bramer, Kelly G. Stratton, Douglas Kempthorne, Aaron R. Navratil, Endale G. Tafesse, Thorsten Hornemann, William B. Messer, Edward A. Dennis, Thomas O. Metz, Eric Barklis, Fikadu G. Tafesse A global lipid map defines a network essential for Zika virus replication Nature Communications 2020-07-21 [PMID: 32694525]
• Wang S, Zhang Q, Tiwari SK et al. Wang S, Zhang Q, Tiwari SK et al. Integrin alpha v beta 5 Internalizes Zika Virus during Neural Stem Cells Infection and Provides a Promising Target for Antiviral Therapy. Cell Rep 2020-01-28 [PMID: 31956073] (ELISA)
• Dragoni F, Boccuto A, Picarazzi F et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro Antiviral Res 2020-01-14 [PMID: 31931104] (ELISA, Virus)
• Durham N, Agrawal A, Waltari E et al. Functional characterization and lineage analysis of broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics bioRxiv 2019-10-02 [PMID: 31820734] (ELISA, Virus)
• Durham ND, Agrawal A, Waltari E et al. Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics Elife 2019-12-10 [PMID: 31820734] (Virus)
• Vogt MB, Lahon A, Arya RP, et al. Dengue viruses infect human megakaryocytes, with probable clinical consequences. PLoS Negl Trop Dis 2019-11-01 [PMID: 31765380] (ICC/IF)
• O'Donnell KL, Meberg B, Schiltz J, Nilles ML, Bradley DS Zika Virus-Specific IgY Results Are Therapeutic Following a Lethal Zika Virus Challenge without Inducing Antibody-Dependent Enhancement. Viruses 2019-03-26 [PMID: 30917523]
• Gold AS Flavivirus-dependent packaging of Aedes aegypti saliva proteins into extracellular vesicles enhances infection Thesis 2023-01-01
• Wollner CJ, Richner M, Hassert MA et al. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses Journal of virology 2021-03-24 [PMID: 33762420] (WB)
• Vicenti I, Dragoni F, Giannini A et Al. Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication SLAS Discov 2020-03-18 [PMID: 32186426]

FAQs for Flavivirus group antigen Antibody (NBP2-52709). (Showing 1 - 1 of 1 FAQs).

1. What is your recommended dilution for this antibody  in Flow Cytometry application?
   • We normally will not have dilutions listed for the conjugated antibodies, only the applications.We would refer you to the unconjugated antibody for the recommended dilution for an application